Cargando…

Reverse genetic systems of SARS-CoV-2 for antiviral research

Reverse genetic systems are widely used to engineer recombinant viruses with desired mutations. In response to the COVID-19 pandemic, four types of reverse genetic systems have been developed for SARS-CoV-2: (i) a full-length infectious clone that can be used to prepare recombinant SARS-CoV-2 at bio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kurhade, Chaitanya, Xie, Xuping, Shi, Pei-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776485/ https://www.ncbi.nlm.nih.gov/pubmed/36657881 http://dx.doi.org/10.1016/j.antiviral.2022.105486

Ejemplares similares

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection
por: Zou, Jing, et al.
Publicado: (2022)

A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation
por: Kotaki, Tomohiro, et al.
Publicado: (2021)

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
por: Hu, Yanping, et al.
Publicado: (2023)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

An Integrated Research–Clinical BSL-2 Platform for a Live SARS-CoV-2 Neutralization Assay
por: Zou, Jing, et al.
Publicado: (2023)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Versatile SARS-CoV-2 Reverse-Genetics Systems for the Study of Antiviral Resistance and Replication
por: Fahnøe, Ulrik, et al.
Publicado: (2022)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

The multiple roles of nsp6 in the molecular pathogenesis of SARS-CoV-2
por: Bills, Cody, et al.
Publicado: (2023)

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
por: Liu, Yang, et al.
Publicado: (2022)

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
por: Liu, Yang, et al.
Publicado: (2022)

S:D614G and S:H655Y are gateway mutations that act epistatically to promote SARS-CoV-2 variant fitness
por: Yurkovetskiy, Leonid, et al.
Publicado: (2023)

Publisher Correction: A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
por: Liu, Yang, et al.
Publicado: (2022)

Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections
por: Zou, Jing, et al.
Publicado: (2022)

Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
por: Muruato, Antonio, et al.
Publicado: (2021)

Evasion of Type I Interferon by SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2020)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Correction for Zhou et al., “Neutralization Titers in Vaccinated Patients with SARS-CoV-2 Delta Breakthrough Infections”
por: Zou, Jing, et al.
Publicado: (2022)

Making sense of spike D614G in SARS-CoV-2 transmission
por: Shi, Aria C., et al.
Publicado: (2021)

Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes
por: Liu, Yang, et al.
Publicado: (2021)

SARS-CoV-2 Antiviral Therapy
por: Tao, Kaiming, et al.
Publicado: (2021)

The arrival of SARS-CoV-2–neutralizing antibodies in a currently available commercial immunoglobulin
por: Miller, Aaron L., et al.
Publicado: (2022)

An antibody that neutralizes SARS-CoV-1 and SARS-CoV-2 by binding to a conserved spike epitope outside the receptor binding motif
por: Fang, Yan, et al.
Publicado: (2022)

A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory
por: Zou, Jing, et al.
Publicado: (2022)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge
por: Muruato, Antonio, et al.
Publicado: (2021)

Identification of the SARS-unique domain of SARS-CoV-2 as an antiviral target
por: Qin, Bo, et al.
Publicado: (2023)

A plasmid DNA-launched SARS-CoV-2 reverse genetics system and coronavirus toolkit for COVID-19 research
por: Rihn, Suzannah J., et al.
Publicado: (2021)

Aminoglycosides and their potential as SARS-CoV-2 antivirals
por: Cimolai, Nevio
Publicado: (2021)

SARS-CoV-2 rebound with and without antivirals
por: Petrosillo, Nicola
Publicado: (2023)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Mutations in SARS-CoV-2 variant nsp6 enhance type-I interferon antagonism
por: Bills, Cody J., et al.
Publicado: (2023)

Immune evasion of SARS-CoV-2 from interferon antiviral system
por: Min, Yuan-Qin, et al.
Publicado: (2021)

Corrigendum to “Discovery of lead natural products for developing pan-SARS-CoV-2 therapeutics” “Antiviral Research 209 (2023)/105484”
por: Perez-Vargas, Jimena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_uelfr0psqf04mpujp5ot5n7fpo